Objective: To assess the effectiveness (extent to which an intervention works in daily medical practice) of the use of phytosterol/phytostanol-enriched margarines to lower total and non-HDL cholesterol levels in users and non-users of statins.

Design: Retrospective cohort study.

Setting: Data were obtained from questionnaires on health and food intake from a population-based longitudinal cohort linked to pharmacy-dispensing records.

Subjects: The analysis included 3829 men and women (aged 31-71 years) who were examined during 1998-2002 and re-examined at 5-year follow-up during 2003-2007.

Results: Recommended doses of margarines were consumed by only 9 % of the subjects. Serum total cholesterol decreased by respectively -0·16 (95 % CI -0·26, -0·05) mmol/l, -1·40 (95 % CI -1·51, -1·30) mmol/l and -1·64 (95 % CI -1·91, -1·37) mmol/l in subjects who started to use phytosterols/phytostanols only, statins only or a combination of both compounds at some point in time between examination and re-examination, compared with subjects who did not start using phytosterols/phytostanols or statins. Cholesterol-lowering effects of the phytosterols/phytostanols were similar in statin users and statin non-users and increased with increasing intake of enriched margarine (no intake, 0; low intake, -0·017 (95 % CI -0·16, 0·13) mmol/l; medium intake, -0·089 (95 % CI -0·22, 0·038) mmol/l; high intake, -0·32 (95 % CI -0·50, -0·14) mmol/l).

Conclusions: Although recommended intake levels of the enriched margarines were not reached by all persons, these data show that under customary conditions of use phytosterols/phytostanols are effective in lowering cholesterol levels in both statin users and non-users.

Download full-text PDF

Source
http://dx.doi.org/10.1017/S1368980011000164DOI Listing

Publication Analysis

Top Keywords

statin users
12
cholesterol-lowering effects
8
users statin
8
statin non-users
8
cholesterol levels
8
users non-users
8
phytosterols/phytostanols statins
8
intake
7
statin
5
mmol/l
5

Similar Publications

Objective: While statins have demonstrated a variety of antineoplastic effects in preclinical studies, several retrospective clinical studies and observational studies have not shown a consistent chemopreventive benefit against prostate cancer (PCa). Therefore, in this population-based cohort study, we examined the association of statin intake on prostate specific antigen (PSA) values and risk of development of PCa.

Method: N = 4,314 men from the Swiss section of the European Randomized Study of Screening for Prostate Cancer (ERSPC) were evaluated.

View Article and Find Full Text PDF

This population-based cohort study aimed to evaluate the risk of osteoporosis and fractures associated with higher-potency statin use compared to lower-potency statin use in patients with stroke, using data from the Health Insurance and Review Assessment database of South Korea (2010-2019). Patients who received statin within 30 days after hospitalization for a new-onset stroke (n = 276,911) were divided into higher-potency (n = 212,215, 76.6%) or lower-potency (n = 64,696, 23.

View Article and Find Full Text PDF

Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of chronic liver disease with a significant risk of developing hepatocellular carcinoma (HCC). Recent clinical evidence indicates the potential benefits of statins in cancer chemoprevention and therapeutics. However, it is still unclear if these drugs can lower the specific risk of HCC among patients with MASLD.

View Article and Find Full Text PDF

Genetic correlation between genes targeted by lipid-lowering drugs and venous thromboembolism: A drug-target Mendelian randomization study.

Medicine (Baltimore)

December 2024

National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.

Dyslipidemia has been established as a potential risk factor for venous thromboembolism (VTE) in several observational studies. Statins and novel lipid-modifying agents are being explored for their potential in VTE prevention, encompassing deep vein thrombosis (DVT), and pulmonary embolism (PE). Nonetheless, conclusive evidence supporting the effectiveness remains uncertain.

View Article and Find Full Text PDF

Assessing real-world effectiveness of atorvastatin in patients with type 2 diabetes mellitus for the primary prevention of cardiovascular events.

Nutr Metab Cardiovasc Dis

November 2024

College of Pharmacy, Kyung Hee University, Seoul, Republic of Korea; Department of Regulatory Science, Graduate School, Kyung Hee University, Seoul, Republic of Korea; Institute of Regulatory Innovation Through Science, Kyung Hee University, Seoul, Republic of Korea. Electronic address:

Background And Aims: In contrast to the substantial body of clinical trial evidence, the real-world evidence regarding the efficacy of statins in the prevention of cardiovascular events among patients with type 2 diabetes mellitus (T2DM) is relatively limited. Therefore, we assessed the effectiveness of atorvastatin for the primary prevention of CV events in patients with T2DM, using a population-based data in South Korea.

Methods And Results: This retrospective cohort study was conducted using the National Health Insurance Service Customized Database (2008-2018) in South Korea.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!